• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酪氨酸激酶抑制剂通过靶向 ATP 结合口袋诱导 c-Kit 的下调。

Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket.

机构信息

Institut Cochin, Département d'Immunologie-Hématologie, Paris, France.

出版信息

PLoS One. 2013 Apr 23;8(4):e60961. doi: 10.1371/journal.pone.0060961. Print 2013.

DOI:10.1371/journal.pone.0060961
PMID:23637779
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3634048/
Abstract

The stem cell factor receptor (SCF) c-Kit plays a pivotal role in regulating cell proliferation and survival in many cell types. In particular, c-Kit is required for early amplification of erythroid progenitors, while it must disappear from cell surface for the cell entering the final steps of maturation in an erythropoietin-dependent manner. We initially observed that imatinib (IM), an inhibitor targeting the tyrosine kinase activity of c-Kit concomitantly down-regulated the expression of c-Kit and accelerated the Epo-driven differentiation of erythroblasts in the absence of SCF. We investigated the mechanism by which IM or related masitinib (MA) induce c-Kit down-regulation in the human UT-7/Epo cell line. We found that the down-regulation of c-Kit in the presence of IM or MA was inhibited by a pre-incubation with methyl-β-cyclodextrin suggesting that c-Kit was internalized in the absence of ligand. By contrast to SCF, the internalization induced by TKI was independent of the E3 ubiquitin ligase c-Cbl. Furthermore, c-Kit was degraded through lysosomal, but not proteasomal pathway. In pulse-chase experiments, IM did not modulate c-Kit synthesis or maturation. Analysis of phosphotyrosine peptides in UT-7/Epo cells treated or not with IM show that IM did not modify overall tyrosine phosphorylation in these cells. Furthermore, we showed that a T670I mutation preventing the full access of IM to the ATP binding pocket, did not allow the internalization process in the presence of IM. Altogether these data show that TKI-induced internalization of c-Kit is linked to a modification of the integrity of ATP binding pocket.

摘要

干细胞因子受体 (SCF) c-Kit 在调节多种细胞类型的细胞增殖和存活中起着关键作用。特别是,c-Kit 是早期红系祖细胞扩增所必需的,而当细胞以依赖促红细胞生成素的方式进入成熟的最后步骤时,它必须从细胞表面消失。我们最初观察到,伊马替尼 (IM),一种针对 c-Kit 酪氨酸激酶活性的抑制剂,同时下调 c-Kit 的表达,并在没有 SCF 的情况下加速促红细胞生成素驱动的红细胞分化。我们研究了 IM 或相关马替尼 (MA) 在缺乏 SCF 的情况下诱导 c-Kit 下调的机制在人类 UT-7/Epo 细胞系中。我们发现,在 IM 或 MA 存在下,c-Kit 的下调被预先孵育甲基-β-环糊精抑制,表明 c-Kit 在没有配体的情况下被内化。与 SCF 不同,TKI 诱导的内化不依赖于 E3 泛素连接酶 c-Cbl。此外,c-Kit 通过溶酶体而不是蛋白酶体途径降解。在脉冲追踪实验中,IM 不会调节 c-Kit 的合成或成熟。在未用 IM 处理或用 IM 处理的 UT-7/Epo 细胞中分析磷酸酪氨酸肽表明,IM 不会改变这些细胞中的整体酪氨酸磷酸化。此外,我们表明,阻止 IM 完全进入 ATP 结合口袋的 T670I 突变,在 IM 存在的情况下不允许内化过程。总之,这些数据表明,TKI 诱导的 c-Kit 内化与 ATP 结合口袋完整性的改变有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5274/3634048/089ab97bc464/pone.0060961.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5274/3634048/439242cbd806/pone.0060961.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5274/3634048/42ba8c1f7365/pone.0060961.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5274/3634048/d2e22b6eb0c5/pone.0060961.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5274/3634048/e39b9c23ef48/pone.0060961.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5274/3634048/a0ccf0916658/pone.0060961.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5274/3634048/23ad48351a73/pone.0060961.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5274/3634048/089ab97bc464/pone.0060961.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5274/3634048/439242cbd806/pone.0060961.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5274/3634048/42ba8c1f7365/pone.0060961.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5274/3634048/d2e22b6eb0c5/pone.0060961.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5274/3634048/e39b9c23ef48/pone.0060961.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5274/3634048/a0ccf0916658/pone.0060961.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5274/3634048/23ad48351a73/pone.0060961.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5274/3634048/089ab97bc464/pone.0060961.g007.jpg

相似文献

1
Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket.酪氨酸激酶抑制剂通过靶向 ATP 结合口袋诱导 c-Kit 的下调。
PLoS One. 2013 Apr 23;8(4):e60961. doi: 10.1371/journal.pone.0060961. Print 2013.
2
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.对甲磺酸伊马替尼耐药的人源c-KIT激活突变对酪氨酸激酶抑制剂PKC412敏感。
Blood. 2005 Jul 15;106(2):721-4. doi: 10.1182/blood-2004-12-4617. Epub 2005 Mar 24.
3
Identification of novel target genes of nerve growth factor (NGF) in human mastocytoma cell line (HMC-1 (V560G c-Kit)) by transcriptome analysis.通过转录组分析鉴定人肥大细胞瘤细胞系(HMC-1(V560G c-Kit))中神经生长因子(NGF)的新靶基因。
BMC Genomics. 2011 Apr 18;12:196. doi: 10.1186/1471-2164-12-196.
4
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.KIT 信号转导调控酪氨酸激酶抑制剂对成熟和原始 CML 祖细胞的敏感性差异。
Cancer Res. 2013 Sep 15;73(18):5775-86. doi: 10.1158/0008-5472.CAN-13-1318. Epub 2013 Jul 25.
5
c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.c-Kit在MYCN扩增的神经母细胞瘤中优先表达,并且其对细胞增殖的作用在体外被STI-571抑制。
Int J Cancer. 2003 Aug 20;106(2):147-52. doi: 10.1002/ijc.11187.
6
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.达沙替尼(BMS-354825)可抑制KITD816V,这是一种对伊马替尼耐药的激活突变,可引发大多数系统性肥大细胞增多症患者的肿瘤生长。
Blood. 2006 Jul 1;108(1):286-91. doi: 10.1182/blood-2005-10-3969. Epub 2006 Jan 24.
7
Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.酪氨酸激酶抑制剂STI571和AG1296可选择性抑制由近膜结构域而非催化结构域突变导致的c-kit组成型激活。
Int J Hematol. 2002 Dec;76(5):427-35. doi: 10.1007/BF02982808.
8
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.试剂盒抑制剂APcK110可诱导急性髓系白血病细胞凋亡并抑制其增殖。
Cancer Res. 2009 May 1;69(9):3910-7. doi: 10.1158/0008-5472.CAN-08-0034. Epub 2009 Apr 21.
9
The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines.甲磺酸伊马替尼对视网膜母细胞瘤细胞系增殖、侵袭能力和放射敏感性的影响。
Eye (Lond). 2013 Jan;27(1):92-9. doi: 10.1038/eye.2012.231. Epub 2012 Nov 16.
10
The G-quadruplex ligand, SYUIQ-FM05, targets proto-oncogene c-kit transcription and induces apoptosis in K562 cells.G-四链体配体 SYUIQ-FM05 靶向原癌基因 c-kit 转录并诱导 K562 细胞凋亡。
Pharm Biol. 2013 Apr;51(4):447-54. doi: 10.3109/13880209.2012.738424. Epub 2013 Jan 30.

引用本文的文献

1
Receptor tyrosine kinase inhibitors negatively impact on pro-reparative characteristics of human cardiac progenitor cells.受体酪氨酸激酶抑制剂对人心脏祖细胞的促修复特性有负面影响。
Sci Rep. 2022 Jun 16;12(1):10132. doi: 10.1038/s41598-022-13203-3.
2
Protein degradation technology: a strategic paradigm shift in drug discovery.蛋白质降解技术:药物发现的战略范式转变。
J Hematol Oncol. 2021 Sep 6;14(1):138. doi: 10.1186/s13045-021-01146-7.
3
Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.

本文引用的文献

1
Stem cell factor receptor/c-Kit: from basic science to clinical implications.干细胞因子受体/c-Kit:从基础科学到临床意义。
Physiol Rev. 2012 Oct;92(4):1619-49. doi: 10.1152/physrev.00046.2011.
2
c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature.c-KIT:肉瘤样特征转移性肾细胞癌索拉非尼疗效的潜在预测因素。
Clin Genitourin Cancer. 2013 Jun;11(2):134-40. doi: 10.1016/j.clgc.2012.08.007. Epub 2012 Oct 9.
3
Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.
胃肠道间质瘤中的增强子域调节 KIT 表达,并可被 BET 溴结构域抑制靶向。
Cancer Res. 2019 Mar 1;79(5):994-1009. doi: 10.1158/0008-5472.CAN-18-1888. Epub 2019 Jan 10.
4
Changes in the interstitial cells of Cajal and neuronal nitric oxide synthase positive neuronal cells with aging in the esophagus of F344 rats.F344大鼠食管中Cajal间质细胞和神经元型一氧化氮合酶阳性神经元细胞随衰老的变化。
PLoS One. 2017 Nov 28;12(11):e0186322. doi: 10.1371/journal.pone.0186322. eCollection 2017.
5
Change in the Interstitial Cells of Cajal and nNOS Positive Neuronal Cells with Aging in the Stomach of F344 Rats.F344大鼠胃中Cajal间质细胞和nNOS阳性神经元细胞随衰老的变化
PLoS One. 2017 Jan 3;12(1):e0169113. doi: 10.1371/journal.pone.0169113. eCollection 2017.
6
Current stage in inflammatory bowel disease: What is next?炎症性肠病的当前阶段:接下来会怎样?
World J Gastroenterol. 2015 Oct 28;21(40):11282-303. doi: 10.3748/wjg.v21.i40.11282.
7
Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5.用靶向KIT膜近端结构域5的抗体中和白血病中的KIT致癌信号传导
Mol Cancer Ther. 2015 Nov;14(11):2595-605. doi: 10.1158/1535-7163.MCT-15-0321. Epub 2015 Sep 10.
8
Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.目前、新出现的以及即将出现的用于治疗炎症性肠病的生物制剂。
Therap Adv Gastroenterol. 2015 Mar;8(2):66-82. doi: 10.1177/1756283X14558193.
9
Sequencing and G-quadruplex folding of the canine proto-oncogene KIT promoter region: might dog be used as a model for human disease?犬原癌基因KIT启动子区域的测序与G-四链体折叠:狗能否用作人类疾病的模型?
PLoS One. 2014 Aug 1;9(8):e103876. doi: 10.1371/journal.pone.0103876. eCollection 2014.
10
The up-regulation of miR-199b-5p in erythroid differentiation is associated with GATA-1 and NF-E2.在红细胞分化过程中,miR-199b-5p的上调与GATA-1和NF-E2相关。
Mol Cells. 2014 Mar;37(3):213-9. doi: 10.14348/molcells.2014.2288. Epub 2014 Mar 6.
索拉非尼抑制与耐药胃肠道间质瘤相关的多种激酶突变。
Mol Cancer Ther. 2012 Aug;11(8):1770-80. doi: 10.1158/1535-7163.MCT-12-0223. Epub 2012 Jun 4.
4
Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.KitV558Δ;T669I/+ 看门突变体小鼠模型中胃肠道间质瘤的伊马替尼耐药和小红细胞性红细胞增多症。
Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):E2276-83. doi: 10.1073/pnas.1115240109. Epub 2012 May 31.
5
Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes.Hsp70 核定位缺陷与骨髓增生异常综合征中的红细胞生成障碍和 GATA-1 切割有关。
Blood. 2012 Feb 9;119(6):1532-42. doi: 10.1182/blood-2011-03-343475. Epub 2011 Dec 12.
6
I787 provides signals for c-Kit receptor internalization and functionality that control mast cell survival and development.I787 为 c-Kit 受体内化和功能提供信号,这些信号控制肥大细胞的存活和发育。
Blood. 2010 Oct 14;116(15):2665-75. doi: 10.1182/blood-2009-06-228460. Epub 2010 Jul 1.
7
Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations.与 KIT 磷酸转移酶结构域突变相比,与儿科肥大细胞增多症相关的 KIT 细胞外结构域突变表现出不同的功能和信号转导特性。
Blood. 2010 Aug 19;116(7):1114-23. doi: 10.1182/blood-2009-06-226027. Epub 2010 May 18.
8
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.马替尼(AB1010),一种针对 KIT 的有效且选择性的酪氨酸激酶抑制剂。
PLoS One. 2009 Sep 30;4(9):e7258. doi: 10.1371/journal.pone.0007258.
9
E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.E3 连接酶缺陷型 Cbl 突变体导致全身性肥大细胞增多症和骨髓增殖性疾病。
Blood. 2009 Nov 5;114(19):4197-208. doi: 10.1182/blood-2008-12-190934. Epub 2009 Sep 4.
10
MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification.MaxQuant可实现高肽段鉴定率、个体化的百万分之一级质量精度以及全蛋白质组范围的蛋白质定量。
Nat Biotechnol. 2008 Dec;26(12):1367-72. doi: 10.1038/nbt.1511. Epub 2008 Nov 30.